[go: up one dir, main page]

Zhou et al., 2017 - Google Patents

Possibility of specific expression of the protein toxins at the tumor site with tumor-specialized promoter

Zhou et al., 2017

Document ID
1717094255836004097
Author
Zhou L
Li Y
Hu C
Wang B
Publication year
Publication venue
Cancer Translational Medicine

External Links

Snippet

The ultimate goal of cancer therapy is to establish a treatment regimen that will ensure complete eradication of cancers with minimal toxicity to the surrounding normal tissues. Protein toxins are highly efficient when they are used as treatment reagents of cancer but …
Continue reading at go.gale.com (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48369—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment
    • A61K47/48507—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site
    • A61K47/48515—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying part being an antibody, an immunoglobulin, or a fragment thereof, e.g. a Fc-fragment the modifying agent being a well defined antibody or immunoglobulin bearing at least one antigen-binding site not used; see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
    • A61K47/48—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
    • A61K47/48238—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid
    • A61K47/48246—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent
    • A61K47/48269—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates the modifying agent being a protein, peptide, polyamino acid drug-peptide, protein or polyamino acid conjugates, i.e. the modifying agent being a protein, peptide, polyamino acid which being linked/complexed to a molecule that being the pharmacologically or therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors, interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations

Similar Documents

Publication Publication Date Title
Yasinjan et al. Immunotherapy: a promising approach for glioma treatment
Shapira et al. Toxin-based therapeutic approaches
FitzGerald et al. Recombinant immunotoxins for treating cancer
Maruoka et al. Near infrared photoimmunotherapy for cancers: A translational perspective
Iwanaga et al. Local delivery system of cytotoxic agents to tumors by focused sonoporation
Weidle et al. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer
Wykosky et al. A novel, potent, and specific ephrinA1-based cytotoxin against EphA2 receptor–expressing tumor cells
Baum et al. Advances in salivary gland gene therapy–oral and systemic implications
Kawakami et al. Analysis of interleukin‐13 receptor α2 expression in human pediatric brain tumors
Qin et al. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models
Li et al. Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma
Debinski Local treatment of brain tumors with targeted chimera cytotoxic proteins
Stokke et al. Antibody–drug conjugates for the treatment of acute pediatric leukemia
Yang et al. Inducible expression of interleukin-12 augments the efficacy of affinity-tuned chimeric antigen receptors in murine solid tumor models
Miura et al. Neo-DREAM study investigating Daromun for the treatment of clinical stage IIIB/C melanoma
Cai et al. Targeted cancer therapy with tumor necrosis factor-alpha
Gong et al. Small-molecule-mediated control of the anti-tumour activity and off-tumour toxicity of a supramolecular bispecific T cell engager
Oh et al. Bispecific targeting of EGFR and urokinase receptor (uPAR) using ligand-targeted toxins in solid tumors
Shay Meeting report: the role of telomeres and telomerase in cancer
Xu et al. Imaging-guided therapy simultaneously targeting HER2 and EpCAM with trastuzumab and EpCAM-directed toxin provides additive effect in ovarian cancer model
Chalabi Stomach cancer gets a triple punch of therapy
Ansell Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells
Vallera et al. Retroviral immunotoxin gene therapy of acute myelogenous leukemia in mice using cytotoxic T cells transduced with an interleukin 4/diphtheria toxin gene
Jacobs et al. Electroporation outperforms in vivo-jetPEI for intratumoral DNA-based reporter gene transfer
Zhou et al. Possibility of specific expression of the protein toxins at the tumor site with tumor-specialized promoter